Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 601–700 of 1,026

1. Mechanism of Action of Immunotherapy
   Mary Lenora Disis · 2014 · Seminars in Oncology
2. The role of neoantigens in response to immune checkpoint blockade
   Nadeem Riaz, Luc G.T. Morris, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Timothy An-thy Chan · 2016 · International Immunology
3. CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy
   Anke Kretz-Rommel, Fenghua Qin, Naveen K. Dakappagari, Edward P. Ravey, John R. McWhirter, Daniela I. Oltean, Shana Frederickson, Toshiaki Maruyama, Martha A. Wild, Mary Jean Nolan et al. · 2007 · The Journal of Immunology
4. Development of immune checkpoint therapy for cancer
   Jill M. Fritz, Michael J. Lenardo · 2019 · The Journal of Experimental Medicine
5. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
   Yuki Katsuya, Yu Fujita, Hidehito Horinouchi, Yuichiro Ohe, Shun-ichi I. WATANABE, Koji Tsuta · 2015 · Lung Cancer
6. Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing
   Pei Y. Teo, Chuan He Yang, Lynsey May Whilding, Ana C. Parente‐Pereira, John F. Maher, Andrew J.T. George, James L. Hedrick, Yi Yan Yang, Sadaf Ghaem‐Maghami · 2015 · Advanced Healthcare Materials
7. B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells
   Shengjia Shi, Lijuan Wang, Guodong Wang, Zhangyan Guo, Ming Wei, Yan–Ling Meng, Angang Yang, Weihong Wen · 2013 · PLoS ONE
8. Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma
   Robert Houston Thompson, Michael D. Gillett, John C. Cheville, Christine Marie Lohse, Haidong Dong, W. Scott Webster, Lieping Chen, Horst Zincke, Michael L. Blute, Bradley C. Leibovich et al. · 2005 · Cancer
9. Comprehensive screening for PD-L1 expression in thyroid cancer
   Soomin Ahn, Tae Hyuk Kim, Sun Wook Kim, Chang‐Seok Ki, Hye Won Jang, Jee Soo Kim, Hyun Jung Kim, Jun‐Ho Choe, Jung Hee Shin, Soo Yeon Hahn et al. · 2017 · Endocrine Related Cancer
10. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
    Piao Li, Tingting Huang, Qi Zou, Dian Liu, Yihua Wang, Ximin Tan, Wei Yao, Hong Qiu · 2019 · The Journal of Immunology
11. Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway
    Xu, Xinjian, Lv, Ji, Guo, Fang, Li, Jing, Jia, Yitao, Jiang, Da, Wang, Na, Zhang, Chao, Kong, Lingyu, Liu, Yabin et al. · 2020 · Frontiers in Microbiology
12. The impact of T‐cell immunity on ovarian cancer outcomes
    Brad H. Nelson · 2008 · Immunological Reviews
13. Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors
    Eva M. Pålsson‐McDermott, Lydia Dyck, Zbigniew Zasłona, Deepthi Menon, Anne F. McGettrick, Kingston H. G. Mills, Luke A.J. O'Neill · 2017 · Frontiers in Immunology
14. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
    Christophe Le Tourneau, Christopher J. Hoimes, Corrine Zarwan, Deborah Jean Lee Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Subramanian Hariharan, Anja von Heydebreck, Vijay Kasturi et al. · 2018 · Journal for ImmunoTherapy of Cancer
15. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
    Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha · 2022 · Immune Network
16. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice
    Miguel F. Sanmamed, Inmaculada Rodríguez, Kurt Alex Schalper, Carmen Oñate, Arantza Azpilikueta, Maria Esperanza Rodriguez-Ruiz, Aizea Morales‐Kastresana, Sara Labiano, José Luis Perez‐Gracia, Salvador Martín‐Algarra et al. · 2015 · Cancer Research
17. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
    Judith Feucht, Simone Kayser, David Gorodezki, Mohamad Hamieh, Michaela Döring, Franziska Blaeschke, Patrick Schlegel, Hans C. Bösmüller, Leticia Quintanilla-Fend, Martin Ebinger et al. · 2016 · Oncotarget
18. B7-H3 role in the immune landscape of cancer.
    Jose R. Castellanos, Ian J. Purvis, Collin M. Labak, Maheedhara Reddy Guda, Andrew J. Tsung, Kiran Kumar Velpula, Swapna Asuthkar · 2017 · Europe PMC (PubMed Central)
19. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection
    Constantinos Petrovas, David A. Price, Joseph J. Mattapallil, David R. Ambrozak, Christof Geldmacher, Valentina Cecchinato, Monica Vaccari, Elżbieta Anna Tryniszewska, Emma Gostick D, Mario Roederer et al. · 2007 · Blood
20. Role of T lymphocytes in tumor response to radiotherapy
    Sandra Demaria, Silvia Chiara Formenti · 2012 · Frontiers in Oncology
21. Tumor Evasion from T Cell Surveillance
    Katrin Töpfer, Stefanie Kempe, Nadja Müller, Marc Schmitz, Michael Philipp Bachmann, Marc Cartellieri, Gabriele Schackert, Achim Temme · 2011 · BioMed Research International
22. Immune privilege in corneal transplantation
    Junko Hori, Takefumi Yamaguchi, Hiroshi Keino, Pedram Hamrah, Kazuichi Maruyama · 2019 · Progress in Retinal and Eye Research
23. Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
    Mingjie Zhang, Li-Feng Huang, Guoping Ding, Huilian Huang, Guoliang Cao, Xu Dong Sun, Neng Lou, Qiang Wei, Tao Shen, Xiaodong Xu et al. · 2020 · Journal for ImmunoTherapy of Cancer
24. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
    Juan Jin, Yuhao Xie, Jin-Shi Zhang, Jing‐Quan Wang, Shi-Jie Dai, Wenfang He, Shou-Ye Li, Charles R. Ashby, Zhe‐Sheng Chen, Qiang He · 2023 · Drug Resistance Updates
25. Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation
    Takanori Kanai∥, Teruji Totsuka, Koji Uraushihara, Shin Makita, Tetsuya Nakamura, Kazutaka Koganei, Tsuneo Fukushima, Hisaya Akiba, Hideo Yagita∥, Ko Okumura et al. · 2003 · The Journal of Immunology
26. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
    Yamauchi, Ichiro, Sakane, Yoriko, Fukuda, Yorihide, Fujii, Toshihito, Taura, Daisuke, Hirata, Masakazu, Hirota, Keisho, Ueda, Yohei, Kanai, Yugo, Yamashita, Yui et al. · 2017 · Thyroid
27. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
    Tang, Bixia, Yan, Xieqiao, Sheng, Xinan, Si, Lu, Cui, Chuanliang, Kong, Yan, Mao, Lili, Lian, Bin, Bai, Xue, Wang, Xuan et al. · 2019 · Journal of Hematology & Oncology
28. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
    Barbara Merelli, Daniela Massi, Laura Cattaneo, Mario Mandalà · 2013 · Critical Reviews in Oncology/Hematology
29. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer
    Jianjie Zhu, Lanxin Chen, Lingting Zou, Panpan Yang, Ruirong Wu, Yong Mao, Huan Zhou, Rui Li, Kaicai Wang, Weipeng Wang et al. · 2014 · Human Immunology
30. Clinical importance of B7-H3 expression in human pancreatic cancer
    I Yamato, Masayuki Sho, Takeo Nomi, T Akahori, Keiji Shimada, Kiyohiko Hotta, H Kanehiro, N Konishi, Hideo Yagita∥, Y. Nakajima · 2009 · British Journal of Cancer
31. Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
    Zhen Zeng, Feng Shi, Lin Zhou, Min-Na Zhang, Yan Chen, Xiujuan Chang, Yin-Ying Lu, Wen-Lin Bai, Jianhui Qu, Chun-Ping Wang et al. · 2011 · PLoS ONE
32. Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
    Ignacio Melero, Antonio Maria Grimaldi, José Luis Perez‐Gracia, Paolo A. Ascierto · 2013 · Clinical Cancer Research
33. Why is melanoma so metastatic?
    Russell R. Braeuer, Ian R. Watson, Chang‐Jiun Wu, Aaron K. Mobley, Takafumi Kamiya, Einav Shoshan, Menashe Bar‐Eli · 2013 · Pigment Cell & Melanoma Research
34. Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma
    Adam J. Gehring, Zi Zong Ho, Anthony Tanoto Tan, Myat Oo Aung, Kang Hoe Lee, Kai Chah Tan, Seng Gee Lim, Antonio Bertoletti · 2009 · Gastroenterology
35. Nivolumab for the treatment of hepatocellular carcinoma
    Fabian Finkelmeier, Oliver Waidmann, Joerg Trojan · 2018 · Expert Review of Anticancer Therapy
36. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
    Zhiyuan Zhu, Hongbo Zhang, Baodong Chen, Xing Liu, Shizhong Zhang, Zhitao Zong, Mengqi Gao · 2020 · Frontiers in Immunology
37. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes
    Arutselvan Natarajan, Aaron T. Mayer, Lingyun Xu, Robert E. Reeves, Jacob J. Gano, Sanjiv Sam Gambhir · 2015 · Bioconjugate Chemistry
38. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
    Céline Berthon, Virginie Driss, Jizhong Liu, Klaudia Kuranda, Xavier P Leleu, Nathalie Jouy, Dominique Hétuin, Bruno Quesnel · 2010 · Cancer Immunology Immunotherapy
39. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet
    Danielle M. Lussier, Eric C. Woolf, John L. Johnson, Kenneth Scott Brooks, Joseph N. Blattman, Adrienne C. Scheck · 2016 · BMC Cancer
40. A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy
    Wenhao Shen, Pei Pei, Chonghai Zhang, Junmei Li, Xiangming Han, Teng Liu, Xiumin Shi, Zhiyue Su, Gaohua Han, Lin Tao Hu et al. · 2023 · ACS Nano
41. Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
    Powell Perng, Michael K. Lim · 2015 · Frontiers in Oncology
42. Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity
    Adriana Albini, Antonino Bruno, Cristina Gallo, G. Pajardi, Douglas McClain Noonan, Katiuscia Dallaglio · 2015 · Connective Tissue Research
43. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
    Naoya Maekawa, Satoru Konnai, Satoshi Takagi, Yumiko Kagawa, Tomohiro Okagawa, Asami Nishimori, Ryoyo Ikebuchi, Yusuke Izumi, Tatsuya Deguchi, Chie Nakajima et al. · 2017 · Scientific Reports
44. Identification of α-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes
    Gee‐Chen Chang, Ko‐Jiunn Liu, Chia‐Ling Hsieh, Tsai-Shu Hu, Suparat Charoenfuprasert, Hsiung-Kun Liu, K T Luh, Li‐Han Hsu, Chew-Wen Wu, Chou‐Chik Ting et al. · 2006 · Clinical Cancer Research
45. A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance
    Antje Habicht, Shirine Dada, Mollie M. Jurewicz, Brian T. Fife, Hideo Yagita∥, Miyuki Azuma, Mohamed H. Sayegh, Indira Guleria · 2007 · The Journal of Immunology
46. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway
    Junghwa Lee, Eunseon Ahn, Haydn Thomas Kissick, Rafi Ahmed · 2015 · Forum on Immunopathological Diseases and Therapeutics
47. Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
    Chrisann Kyi, Michael Andrew Postow · 2016 · Immunotherapy
48. RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
    Hidetoshi Sumimoto, Atsushi Takano, Koji Teramoto, Yataro Daigo · 2016 · PLoS ONE
49. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
    Marzia Palma, Giusy Gentilcore, Kia Heimersson, Fariba Mozaffari, Barbro Näsman‐Glaser, Emma Young, Richard Rosenquist, Lotta Hansson, Anders Österborg, Håkan Mellstedt · 2016 · Haematologica
50. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
    Chen, Jiao, Feng, Yun, Lu, Libing, Wang, Hui, Dai, Lina, Li, Yan, Zhang, Ping · 2012 · Immunobiology
51. The Transcription Factor NFAT Exhibits Signal Memory during Serial T Cell Interactions with Antigen-Presenting Cells
    Francesco Marangoni, Thomas T. Murooka, Teresa Manzo, Edward Y. Kim, Esteban Carrizosa, Natalie M. Elpek, Thorsten R. Mempel · 2013 · Immunity
52. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
    MacLean S. Hall, Hao Liu, Mokenge Peter Malafa, Barbara Ann Centeno, Pamela Joy Hodul, José M. Pimiento, Shari Pilon‐Thomas, Amod A. Sarnaik · 2016 · Journal for ImmunoTherapy of Cancer
53. The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer
    André Steven, Barbara Seliger · 2018 · Breast Care
54. Dendritic cell therapy in cancer treatment; the state-of-the-art
    Mahsa Sadeghzadeh, Soghra Bornehdeli, Haniye Mohahammadrezakhani, Mahsa Abolghasemi, Elham Poursaei, Milad Asadi, Venus Zafari, Leili Aghebati Maleki, Dariush Shanehbandi · 2020 · Life Sciences
55. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
    Yi, Ming, Niu, Mengke, Zhang, Jing, Li, Shiyu, Zhu, Shuangli, Yan, Yongxiang, Li, Ning, Zhou, Pengfei, Chu, Qian, Wu, Kongming · 2021 · Journal of Hematology & Oncology
56. Lenalidomide enhances anti-myeloma cellular immunity
    Luptakova, Katarina, Rosenblatt, Jacalyn, Glotzbecker, Brett, Mills, Heidi, Stroopinsky, Dina, Kufe, Turner, Vasir, Baldev, Arnason, Jon, Tzachanis, Dimitri, Zwicker, Jeffrey I. et al. · 2013 · Cancer Immunology, Immunotherapy
57. PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
    Julien J. Fourcade, Pavol Kudela, Zhaojun Sun, Hongmei Shen, Stephanie R. Land, Diana E. Lenzner, Philippe Guillaume, Immanuel F. Luescher, Cindy Sander, Soldano Ferrone et al. · 2009 · The Journal of Immunology
58. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?
    Michael R. Shurin, Galina V. Shurin, Anna E Lokshin, Zoya R. Yurkovetsky, Dmitry W. Gutkin, Gurkamal S. Chatta, Hua Zhong, Baohui Han, Robert Louis Ferris · 2006 · Cancer and Metastasis Reviews
59. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
    Chiao-Wen Kang, Avijit Dutta, Li-Yuan Chang, Jayashri Mahalingam, Yung‐Chang Lin, Jy‐Ming Chiang, Chen-Yu Hsu, Ching‐Tai Huang, Wanting Su, Yu‐Yi Chu et al. · 2015 · Scientific Reports
60. Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Jessica M. Moskovitz, Jennifer D. Moy, Robert Louis Ferris · 2018 · Current Oncology Reports
61. Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
    Mark Anthony Perazella, Anushree C. Shirali · 2018 · Journal of the American Society of Nephrology
62. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
    Jihane Boustani, M. Grapin, Pierre-Antoine Laurent, Lionel Apétoh, Céline Mirjolet · 2019 · Cancers
63. TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence
    Ye, Jian, Ma, Chunling, Hsueh, Eddy C, Dou, Jie, Mo, Wei, Liu, Shuai, Han, Bing, Huang, Yi, Zhang, Yanping, Varvares, Mark A et al. · 2014 · EMBO Molecular Medicine
64. Isopentenyl Pyrophosphate–Activated CD56+ γδ T Lymphocytes Display Potent Antitumor Activity toward Human Squamous Cell Carcinoma
    Alan A. Z. Alexander, Amudhan Maniar, Jean-Saville Cummings, Andrew M. Hebbeler, Dan H. Schulze, Brian Gastman, C. David Pauza, Scott Eric Strome, Andrei I. Chapoval · 2008 · Clinical Cancer Research
65. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Benjamin Herzberg, Meghan J. Campo, Justin F. Gainor · 2016 · The Oncologist
66. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
    Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, Nicola Tumino, Paola Vacca, Lorenzo Moretta · 2020 · Cancers
67. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection
    Sumit Kumar Subudhi, Ping Zhou, Lisa M. Yerian, Robert Chin, James C. Lo, Robert A. Anders, Yonglian Sun, Lieping Chen, Yang Wang, Maria‐Luisa Alegre et al. · 2004 · Journal of Clinical Investigation
68. Antitumor Immunity and Cancer Stem Cells
    Tobias Schatton, Markus H. Frank · 2009 · Annals of the New York Academy of Sciences
69. Potential targeting of B7‐H4 for the treatment of cancer
    Joseph R. Podojil, Stephen D. Miller · 2017 · Immunological Reviews
70. PD-1 and cancer: molecular mechanisms and polymorphisms
    Arash Salmaninejad, Vahid Khoramshahi, Alireza Azani, Ehsan Soltaninejad, Saeed Aslani, Mohammad Reza Zamani, Masoud Zal, Abolfazl Nesaei, Sayed Mostafa Hosseini · 2017 · Immunogenetics
71. Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment
    Ronan Thibaut, Pierre Bost, Idan Milo, Marine Cazaux, Fabrice Lemaı̂tre, Zacarias Garcia, Ido Amit, Béatrice Bréart, Clémence Cornuot, Benno Schwikowski et al. · 2020 · Nature Cancer
72. Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor
    Tahiro Shin, Gene Kennedy, Kevin S. Gorski, Haruo Tsuchiya, Haruhiko Koseki, Miyuki Azuma, Hideo Yagita∥, Lieping Chen, Jonathan D. Powell, Drew M. Pardoll et al. · 2003 · The Journal of Experimental Medicine
73. Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS
    Tim Magnus, Bettina Schreiner, Thomas Korn, Carolyn S. Jack, Hong Guo, Jack Perry Antel, Igal Ifergan, Lieping Chen, Felix Bischof, Amit Bar‐Or et al. · 2005 · Journal of Neuroscience
74. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells
    Sasidharan Nair, Varun, Toor, Salman M., Ali, Bassam R., Elkord, Eyad · 2018 · Expert Opinion on Therapeutic Targets
75. GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
    Vincent G. Brichard, Diane Lejeune · 2007 · Vaccine
76. Nivolumab in melanoma: latest evidence and clinical potential
    Douglas Buckner Johnson, Chengwei Peng, Jeffrey Alan Sosman · 2015 · Therapeutic Advances in Medical Oncology
77. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression
    Daria Trabattoni · 2002 · Blood
78. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment
    J. David Peske, Amber B. Woods, Víctor H. Engelhard · 2015 · Advances in cancer research
79. PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient
    Zhenhua Li, Pengzhi Dong, Meijing Ren, Yawen Song, Xiaolong Qian, Yiling Yang, Shuai Li, Xinmin Zhang, Fangfang Liu · 2016 · Journal of Cancer
80. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes
    Sasagu Kurozumi, Yuri Yamaguchi, Masafumi Kurosumi, Miki Ohira, Hiroshi Matsumoto, Jun Horiguchi · 2016 · Journal of Human Genetics
81. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages
    Erik A. Dill, Alejandro Ariel Gru, Kristen A. Atkins, Lisa A. Friedman, Margaret E. Moore, Timothy N. J. Bullock, Janet V. Cross, Patrick Michael Dillon, Anne M. Mills · 2017 · The American Journal of Surgical Pathology
82. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
    Shona A. Hendry, David J. Byrne, Gavin Michael Wright, Richard J. Young, Sue Sturrock, Wendy A. Cooper, Stephen B. Fox · 2017 · Journal of Thoracic Oncology
83. Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
    Venkatesh Sivanandam, Christopher James LaRocca, Nanhai G. Chen, Yuman Fong, Susanne Gray Warner · 2019 · Molecular Therapy — Oncolytics
84. The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
    Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, Kavita A. Iyer, Krittika Ralhan, Yacidzohara Rodríguez, Qiongqiong Angela Zhou · 2023 · Bioconjugate Chemistry
85. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells
    Atsushi Nakazawa, Iris Dotan, Jens Brimnes, Matthieu Allez, Ling Shao, Fumihiko Tsushima, Miyuki Azuma, Lloyd Mayer · 2004 · Gastroenterology
86. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma
    Mei-Chi Hsu, Jenn‐Ren Hsiao, Kung‐Chao Chang, Yuan-Hua Wu, Ih‐Jen Su, Ying‐Tai Jin, Yao Chang · 2010 · Modern Pathology
87. Expression of B7‐H1 in breast cancer patients is strongly associated with high proliferative Ki‐67‐expressing tumor cells
    Hazem Ghebeh, Asma M. Tulbah, Shamayel F. Mohammed, Naser B. Elkum, Suad M. Bin Amer, Taher Al‐Tweigeri, Said Dermime · 2007 · International Journal of Cancer
88. PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
    Shenyou Sun, Xiaochun Fei, Yan Mao, Xiumin Wang, David H. Garfield, Ou Huang, Jinglong Wang, Fei Yuan, Long Sun, Qixiang Yu et al. · 2014 · Cancer Immunology Immunotherapy
89. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance
    Yalan Deng, Xianghou Xia, Yang Zhao, Zilong Zhao, Consuelo Martinez, Wenjuan Yin, Jun Yao, Qinglei Hang, Wei-Che Wu, Jie Zhang et al. · 2021 · Nature Communications
90. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
    Lucia B. Jilaveanu, Brian M. Shuch, Christopher R. Zito, F. Parisi, Meaghan L. Barr, Yuval Kluger, Lieping Chen, Harriet M. Kluger · 2014 · Journal of Cancer
91. Immune checkpoint inhibition in ovarian cancer
    Junzo Hamanishi, Masaki Mandai, Ikuo Konishi · 2016 · International Immunology
92. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients
    Yongping Zhou, Qian Wei, Junsheng Fan, Sijin Cheng, Wenzhou Ding, Zhiyuan Hua · 2018 · Clinica Chimica Acta
93. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
    Hari Menon, Rishab Ramapriyan, Taylor R. Cushman, Vivek Verma, Hans H. Kim, Jonathan E. Schoenhals, Semra Cemre Atalar, Uğur Selek, Stephen G. Chun, Joe Yujiao Chang et al. · 2019 · Frontiers in Immunology
94. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
    Atsuko Kitano, Makiko Ono, Masayuki Yoshida, Emi Noguchi, Akihiko Shimomura, Tatsunori Shimoi, Makoto Kodaira, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu et al. · 2017 · ESMO Open
95. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
    Yufan Qiu, Yi Yang, Ri‐Yao Yang, Chunxiao Liu, Jung-Mao Hsu, Zhou Jiang, Linlin Sun, Yongkun Wei, Chia‐Wei Li, Dihua Yu et al. · 2021 · Oncogene
96. Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy
    Woo‐Sung Chang, Jiyeon Kim, Yeon‐Jeong Kim, Yun-Sun Kim, Jung-Mi Lee, Miyuki Azuma, Hideo Yagita∥, Chang‐Yuil Kang · 2008 · The Journal of Immunology
97. Inhibitory receptors as targets for cancer immunotherapy
    Meghan E. Turnis, Lawrence Peter Andrews, Dario A.A. Vignali · 2015 · European Journal of Immunology
98. Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis
    Julie A. Stortz, Tyler J. Murphy, Steven L. Raymond, Juan C. Mira, Ricardo F. Ungaro, Marvin L. S. Dirain, Dina C. Nacionales, Tyler John Loftus, Zhongkai Wang, Tezcan Ozrazgat‐Baslanti et al. · 2017 · Shock
99. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
    Kellsye P. Fabian, Michelle R. Padget, Renee Nicole Donahue, Kristen Solocinski, Yvette L. Robbins, Clint Tanner Allen, John H. Lee, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom et al. · 2020 · Journal for ImmunoTherapy of Cancer
100. Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels
     Chenfei Zhou, Wen-Fei Wei, Jing Ma, Yang Yang, Luo-Jiao Liang, Yanmei Zhang, Zi‐Ci Wang, Xiaojing Chen, Lei Huang, Wei Wang et al. · 2020 · Molecular Therapy